Skip to content

ENSYSCE BIOSCIENCES, INC.: 10-K/A filed 2021-06-08

What ENSYSCE BIOSCIENCES, INC. reported in its annual report amendment filed 2021-06-08 (fiscal FY 2020): 19 published measures, 90 facts as tagged in accession 0001493152-21-013767.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2021-06-08
Fiscal period
fiscal FY 2020
Accession
0001493152-21-013767 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENSYSCE BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-12-3112,854,634USD
At 2019-12-31196,511,899USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-12-3114,061,692USD
At 2020-09-3011,774,370USD
At 2020-06-3016,106,619USD
At 2020-03-3157,084,161USD
At 2019-12-3117,503,563USD
At 2019-09-3013,662,341USD
At 2019-06-3013,162,102USD
At 2019-03-3112,778,999USD
At 2018-12-3113,172,650USD
At 2018-09-3014,661,902USD
At 2018-06-3012,731,744USD
At 2018-03-3112,520,931USD
At 2017-12-3112,820,989USD
At 2017-12-0511,779,682USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-12-31-1,207,058USD
At 2020-09-301,515,005USD
At 2020-06-30-2,694,568USD
At 2020-03-314,517,562USD
At 2019-12-315,000,001USD
At 2019-09-305,000,001USD
At 2019-06-305,000,001USD
At 2019-03-315,000,001USD
At 2018-12-315,000,001USD
At 2018-09-305,000,001USD
At 2018-06-305,000,001USD
At 2018-03-315,000,001USD
At 2017-12-315,000,001USD
At 2017-12-055,000,004USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-12-314,310,769USD366
2019-01-01 to 2019-12-31-1,067,296USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-864,439USD366
2019-01-01 to 2019-12-31-1,424,792USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-183,551,163USD366
2019-01-01 to 2019-12-31-11,025,845USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-12-31183,403,653USD366
2019-01-01 to 2019-12-3111,853,390USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-12-31-1,207,680USD
At 2020-09-301,514,383USD
At 2020-06-30-2,695,190USD
At 2020-03-311,656,012USD
At 2019-12-31-136,706USD
At 2019-09-302,819,878USD
At 2019-06-302,466,655USD
At 2019-03-312,047,753USD
At 2018-12-31930,590USD
At 2018-09-30-1,362,368USD
At 2018-06-30-233,767USD
At 2018-03-31-375,877USD
At 2017-12-31-1,123,193USD
At 2017-12-05-5,161USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-12-31244,493USD366
2019-01-01 to 2019-12-31555,200USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-1,368,841USD366
2019-01-01 to 2019-12-31-3,328,674USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-12-31226,464USD
At 2019-12-311,199,722USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-12-31260,404USD
At 2019-12-312,771,025USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2020-01-01 to 2020-12-31184,776,163USD366
2020-03-30 to 2020-03-31136,283,492USD2
2019-01-01 to 2019-12-3111,583,473USD365

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-12-311,368,841USD366
2019-01-01 to 2019-12-313,328,674USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-12-316,224,268shares
At 2019-12-317,067,422shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-12-315,136,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-12-314,555,262USD366
2019-01-01 to 2019-12-31-512,096USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-01-01 to 2020-12-314,310,769USD366
2020-07-01 to 2020-09-304,209,573USD92
2020-01-01 to 2020-09-306,889,453USD274
2020-04-01 to 2020-06-30887,162USD91
2020-01-01 to 2020-06-302,679,880USD182
2020-01-01 to 2020-03-311,792,718USD91
2019-01-01 to 2019-12-31-1,067,296USD365
2019-07-01 to 2019-09-30353,223USD92
2019-01-01 to 2019-09-301,889,288USD273
2019-04-01 to 2019-06-30418,902USD91
2019-01-01 to 2019-06-301,536,065USD181
2019-01-01 to 2019-03-311,117,163USD90
2018-01-01 to 2018-12-312,053,783USD365
2018-07-01 to 2018-09-30-1,128,601USD92
2018-01-01 to 2018-09-30-239,175USD273
2018-04-01 to 2018-06-30142,110USD91
2018-01-01 to 2018-06-30889,426USD181
2018-01-01 to 2018-03-31747,316USD90
2017-09-12 to 2017-12-31-1,123,193USD111

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-1,764USD365

Inspect the source

Entity
ENSYSCE BIOSCIENCES, INC. / CIK 0001716947
Captured
2026-09-21T17:24:39.335Z
SEC response SHA-256
28573a09f81da1511239531464c03b2552a3554a684a233653f365b194b6ca0b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001716947.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))